Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHESA: N0877 vs Benicar HCT in Essential Arterial Hypertension
NCT06608472Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Jan 2027
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of N-0877 in essential hypertension (2 arms), sponsored by Eurofarma. Primary endpoint: Mean change in Systolic Blood Pressure at 8 weeks. Planned start Jan 2027; status: withdrawn.
02
Drugs
N-0877
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06608472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608472.